Canaccord raised the firm’s price target on Vertex Pharmaceuticals to $376 from $371 and keeps a Sell rating on the shares. The firm updated its model to reflect the the $4.4B IPR&D charge in 2Q24; where they had previously been over-accounting for the transaction.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- Vertex Pharmaceuticals Inc. (VRTX) Q2 Earnings Cheat Sheet
- Vertex Pharmaceuticals price target raised to $500 from $462 at H.C. Wainwright
- Vertex Pharmaceuticals expands drug discovery collaboration with Genomics
- Vertex sues HHS over fertility support program, Reuters reports
- Vertex Pharmaceuticals CMO Bozic sells 2,280 common shares